« Return to News | Awards & Advancement

Novavax appoints Stanley C. Erck as president and CEO

Wednesday, April 20, 2011 12:02 PM

Novavax’s Stanley C. Erck, its former executive chairman, has been appointed to the position of president and chief executive officer and will remain as a member of the board of directors. Current board member James Young, Ph.D., will assume the position of chairman of the board.

Erck has had experience in the biotechnology sector and has brought infectious disease product candidates into late-stage clinical trials for Novavax. From 2000-2008, Erck served as president and CEO of Iomai Corporation, leading the company through an IPO and a merger with Intercell. He also served as president and CEO of Procept, a publicly-traded immunology company; as vice president of corporate development at Integrated Genetics, and in management positions within Baxter International.

Young has over 30 years of experience in the fields of molecular genetics, microbiology, immunology and pharmaceutical development. He was previously president of R&D at MedImmune where he was instrumental in the development of FluMistR and SynagisR.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.